Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology remibrutinib - BTK inhibitor 2023 priorities Innovation: Clinical trials Neuroscience Oncology remibrutinib - BTK inhibitor Appendix Abbreviations Other NCT05147220 REMODEL-1 (CLOU064C12301) Indication Multiple sclerosis Indication NCT05156281 REMODEL-2 (CLOU064C12302) Multiple sclerosis Phase Phase 3 Phase Phase 3 Patients 800 Patients 800 Primary Outcome Measures Annualized relapse rate (ARR) of confirmed relapses [Core Part]. ARR is the average number of confirmed MS relapses in a year Primary Annualized relapse rate (ARR) of confirmed relapses Outcome Measures Arms Intervention Arm 1: Experimental; Remibrutinib - Core (Remibrutinib tablet and matching placebo of teriflunomide capsule) Arms Arm 1: Experimental; Remibrutinib - Core Intervention Arm 2: Active Comparator; Teriflunomide - Core (Teriflunomide capsule and matching placebo remibrutinib tablet) Target Patients Arm 3: Experimental; Remibrutinib - Extension (Participants on remibrutinib in Core will continue on remibrutinib tablet) Arm 4: Experimental; Remibrutinib - Extension (on teriflunomide in Core) (Participants on teriflunomide in Core will switch to remibrutinib tablet) Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 Readout Milestone(s) Publication TBD 79 Investor Relations | Q4 2022 Results Remibrutinib tablet and matching placebo of teriflunomide capsule Arm 2: Active Comparator; Teriflunomide - Core Teriflunomide capsule and matching placebo remibrutinib tablet Arm 3: Experimental: Remibrutinib - Extension Participants on remibrutinib in Core will continue on remibrutinib tablet Arm 4: Experimental: Remibrutinib - Extension (on teriflunomide in Core) Participants on teriflunomide in Core will switch to remibrutinib tablet Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 Target Patients Readout Milestone(s) Publication TBD NOVARTIS | Reimagining Medicine

View entire presentation